GlassScriptPhysician profile
Jason J Wu
NPI 1598024507
$4,168.82
in general payments reported to CMS, 2019-2025
27 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $27.83 · 2021: $378 · 2022: $678 · 2023: $548 · 2024: $951 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.01 |
| Education | $216.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $871.09 | 2021-2025 | |
| Amgen INC. | $603.44 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Janssen Biotech, INC. | $536.52 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $436.92 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $285.88 | 2019-2025 | Cimzia, Bimzelx |
| Genentech USA, INC. | $271.15 | 2019-2023 | Actemra |
| Ferring Pharmaceuticals INC. | $204.21 | 2019-2025 | Euflexxa |
| Pfizer INC. | $197.74 | 2019-2025 | |
| Horizon Therapeutics Plc | $117.81 | 2019-2023 | Krystexxa |
| Bioventus LLC | $99.83 | 2019-2025 | Durolane |
| Genzyme Corporation | $67.50 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $63.37 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $46.53 | 2025 | Orencia |
| Hikma Pharmaceuticals USA | $41.17 | 2019-2022 | |
| Lilly USA, LLC | $39.33 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $38.25 | 2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $36.82 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $33.76 | 2022 | |
| Glaxosmithkline, LLC. | $30.75 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.16 | 2019-2024 | Cyltezo |
| Depuy Synthes Sales INC. | $24.21 | 2025 | Truespan Orthocord, Healix Knotless Peek, Dynacord |
| Djo, LLC | $18.46 | 2023 | Aircast, Donjoy |
| Alkermes, INC. | $18.25 | 2021 | |
| Avanos Medical | $15.42 | 2025 | Trivisc Sodium Hyaluronate |
| Organon LLC | $14.45 | 2025 | Hadlima |
| Endo Pharmaceuticals INC. | $14.11 | 2021 | |
| Medexus Pharma, INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.